Clinical Ink Announces eSource Partnership With ePharmaSolutions; Launches SureSource 3.0
Clinical Ink announces a partnership with ePharmaSolutions to replace paper source documents at a research site with electronic forms for use in complex psychiatric and neurological studies. Simultaneously, Clinical Ink disclosed that it has secured an additional $2.7 Million in debt and equity financing to create the market for SureSource™, an electronic source record application.
"Our relationship with Clinical Ink will (hope to ) set a new standard for completion of these forms by incorporating real time data validation and scoring to eliminate the expense and burden of reconciling these errors later in the study," said Lance Converse, Founder and CEO of ePharmaSolutions. "We have also integrated our proprietary remote video capture technology with Clinical Ink's intelligent eSource technology to simultaneously capture both the scoring data and an audio/visual record of the patient interactions. This patient record can be used to conduct independent diagnosis confirmation, data monitoring and adjudication, and interview skills assessment throughout the study."
The financing includes new investment by the management team and existing investors, new private investors, as well as a line of credit through Sun Trust Bank. Funds will be used to build a sales and service organization and to further develop the SureSource platform to capture other types of paper source documents as eSource.
Clinical Ink also announces the availability of SureSource 3.0 which has been fully validated in compliance with FDA regulations. This latest version incorporates auto-save and recovery technology that eliminates the possibility of data loss due to connectivity or hardware failure.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
